Monoamine oxidase A: An emerging therapeutic target in prostate cancer.

antiandrogen therapy castration resistance metastasis monoamine oxidase A prostate cancer tumor-stromal interaction

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 03 01 2023
accepted: 30 01 2023
entrez: 2 3 2023
pubmed: 3 3 2023
medline: 3 3 2023
Statut: epublish

Résumé

Monoamine oxidase A (MAOA), a mitochondrial enzyme degrading biogenic and dietary amines, has been studied in the contexts of neuropsychiatry and neurological disorders for decades, but its importance in oncology, as best exemplified in prostate cancer (PC) to date, was only realized recently. PC is the most commonly diagnosed non-skin cancer and the second deadliest malignancy for men in the United States. In PC, the increased expression level of MAOA is correlated with dedifferentiated tissue microarchitecture and a worse prognosis. A wealth of literature has demonstrated that MAOA promotes growth, metastasis, stemness and therapy resistance in PC, mainly by increasing oxidative stress, augmenting hypoxia, inducing epithelial-to-mesenchymal transition, and activating the downstream principal transcription factor Twist1-dictated multiple context-dependent signaling cascades. Cancer-cell-derived MAOA also enables cancer-stromal cell interaction involving bone stromal cells and nerve cells by secretion of Hedgehog and class 3 semaphorin molecules respectively to modulate the tumor microenvironment in favor of invasion and metastasis. Further, MAOA in prostate stromal cells promotes PC tumorigenesis and stemness. Current studies suggest that MAOA functions in PC in both cell autonomous and non-autonomous manners. Importantly, clinically available monoamine oxidase inhibitors have shown promising results against PC in preclinical models and clinical trials, providing a great opportunity to repurpose them as a PC therapy. Here, we summarize recent advances in our understanding of MAOA roles and mechanisms in PC, present several MAOA-targeted strategies that have been nominated for treating PC, and discuss the unknowns of MAOA function and targeting in PC for future exploration.

Identifiants

pubmed: 36860320
doi: 10.3389/fonc.2023.1137050
pmc: PMC9968829
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1137050

Subventions

Organisme : NCI NIH HHS
ID : R01 CA258634
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA233658
Pays : United States

Informations de copyright

Copyright © 2023 Chen and Wu.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
Oncogene. 2021 Apr;40(17):3087-3100
pubmed: 33795839
iScience. 2021 Jan 01;24(1):101970
pubmed: 33437943
Science. 1995 Jun 23;268(5218):1763-6
pubmed: 7792602
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):61-68
pubmed: 32123315
Sci Immunol. 2021 May 14;6(59):
pubmed: 33990379
Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37
pubmed: 20585344
Oncogene. 2020 Apr;39(16):3305-3321
pubmed: 32066880
J Clin Invest. 2014 Jul;124(7):2891-908
pubmed: 24865426
PLoS Genet. 2021 Jan 29;17(1):e1008540
pubmed: 33513133
J Am Chem Soc. 2015 Feb 18;137(6):2366-74
pubmed: 25585152
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Br J Cancer. 2015 Jul 14;113(2):242-51
pubmed: 26103574
Differentiation. 2008 Sep;76(7):820-30
pubmed: 18248494
Hum Genet. 1998 Sep;103(3):273-9
pubmed: 9799080
BMC Med Genomics. 2010 Sep 24;3:43
pubmed: 20868494
Nat Med. 2000 Jun;6(6):703-6
pubmed: 10835690
BMC Cancer. 2020 Jun 18;20(1):572
pubmed: 32552802
Sci Rep. 2017 Apr 12;7:46338
pubmed: 28402333
J Pathol. 2017 Oct;243(2):220-229
pubmed: 28722111
Oncogene. 2021 Feb;40(7):1362-1374
pubmed: 33420365
Molecules. 2019 Jan 24;24(3):
pubmed: 30678358
Prostate. 2014 Jan;74(1):70-89
pubmed: 24115221
Science. 2002 Aug 2;297(5582):851-4
pubmed: 12161658
Int J Oncol. 2015 Dec;47(6):2064-72
pubmed: 26499200
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Front Oncol. 2021 Feb 01;10:571308
pubmed: 33598420
Int J Mol Sci. 2017 Dec 20;18(12):
pubmed: 29261141
Oncotarget. 2017 Dec 7;8(70):114481-114494
pubmed: 29383096
Oncogene. 2018 Sep;37(38):5175-5190
pubmed: 29844571
J Cereb Blood Flow Metab. 2013 Jun;33(6):863-71
pubmed: 23403377
Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1527-33
pubmed: 18652859
Cancer Cell. 2017 Mar 13;31(3):368-382
pubmed: 28292438
Prostate. 2019 May;79(6):667-677
pubmed: 30693539
Curr Ther Res Clin Exp. 2020 Oct 28;93:100610
pubmed: 33245296
Endocrinology. 2004 Aug;145(8):3913-24
pubmed: 15131019
Pharmacogn Mag. 2016 May;12(Suppl 2):S116-20
pubmed: 27279695
Biol Psychiatry. 2014 Jan 1;75(1):9-17
pubmed: 23786983
N Engl J Med. 2014 Sep 11;371(11):1028-38
pubmed: 25184630
Medchemcomm. 2018 Jun 8;9(7):1164-1171
pubmed: 30109004
J Urol. 2008 Nov;180(5):2206-11
pubmed: 18804811
Science. 2017 Nov 17;358(6365):941-946
pubmed: 29025995
Ecotoxicol Environ Saf. 2021 Oct 1;222:112504
pubmed: 34265533
Front Oncol. 2019 Aug 28;9:801
pubmed: 31555580
Annu Rev Neurosci. 1999;22:197-217
pubmed: 10202537
Med Sci Monit. 2012 Dec;18(12):BR482-6
pubmed: 23197227
Prostate. 2012 Nov;72(15):1622-7
pubmed: 22473857
Cell. 2013 Dec 5;155(6):1309-22
pubmed: 24315100
Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):10991-6
pubmed: 16829574
Nat Commun. 2021 Jun 10;12(1):3530
pubmed: 34112755
Biochem Biophys Res Commun. 2019 Oct 29;519(1):153-159
pubmed: 31481238
J Neurosci. 2008 May 7;28(19):5099-104
pubmed: 18463263
Oncol Lett. 2018 Mar;15(3):3245-3251
pubmed: 29435065
Biochem Biophys Res Commun. 2022 May 28;606:135-141
pubmed: 35349822
Nat Commun. 2020 Jun 1;11(1):2689
pubmed: 32483206
J Cancer Res Clin Oncol. 2010 Nov;136(11):1761-71
pubmed: 20204405
Oncotarget. 2016 Mar 22;7(12):13842-53
pubmed: 26871599
BMC Genomics. 2008 Mar 20;9:134
pubmed: 18366702
PLoS One. 2014 Sep 08;9(9):e104271
pubmed: 25198178
Cancer Res. 2021 Aug 15;81(16):4275-4289
pubmed: 34167949

Auteurs

Chia-Hui Chen (CH)

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.

Boyang Jason Wu (BJ)

Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, United States.

Classifications MeSH